Corresponding Author: Sepehr Bahadorani, MD, PhD. Department of Ophthalmology, University of Texas Health, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. Central retinal artery occlusion (CRAO) is an ophthalmic emergency and yet, no standardized management protocol exists for this disease. Over years, multiple CRAO management strategies have been proposed, including ocular massage, intraocular pressure lowering therapies, administration of thrombolytic agents, and supplemental oxygenation such as hyperbaric oxygen therapy (HBOT). The goal of these treatments is to increase blood flow and oxygenation to the ischemic inner retina. Nevertheless, none has consistently been shown to improve visual outcome following CRAO [1-5].
Similarly, HBOT has been employed as a potential management strategy in CRAO. It has been proposed that HBOT may limit ischemic retinal damage between the onset of CRAO and retinal artery recanalization, which typically occurs within 72 hours [6]. However, controversy remains regarding the effectiveness of this treatment modality in final visual outcome. Hence, the goal of this study is to understand the potential visual benefits of HBOT in the treatment of CRAO by performing a systematic review and to compare meta-analysis results to outcomes at our own clinical setting.
Materials and Methods
This study was approved by the institutional review board of University of Texas Health. Due to the retrospective nature of the study, written informed consent was waived.
We have conducted this study in accordance with widely accepted PRISMA (preferred reporting items for systematic review and meta-analysis) guidelines [7], with each stage of the study carried out by two researchers independently (SB and LR).
Search strategy and selection criteria
We have searched the PubMed, Scopus, and the Cochrane Library from the date of database inception to September 2021, searching for the following keywords: “oxygen central retinal artery occlusion.” Inclusion criteria included patients with CRAO treated with HBOT and primary outcome assessment with initial and final visual acuity (mean ± standard deviation). Exclusion criteria included non-English articles, case reports, reviews, and noncomparative data. The title and/or abstracts were reviewed by SB and LR independently, after which the full text of selected articles was reviewed.
Data extraction and quality assessment
Information on the first author, publication date, study design, sample size, initial and final visual outcome, mean elapsed time between symptom onset and treatment, and inclusion of adjunct therapies is extracted from selected studies. Egger’s and Begg’s quality assessment tests were not performed due to a small number of selected studies.
Statistical analysis
The RevMan ver. 5.4 software (Cochrane Collaboration, Copenhagen, Denmark) was used to assess continuous variable outcomes of visual acuity using the weighted mean difference, and the overall effect size with 95% confidence interval was calculated using a random model. The heterogeneity of studies was accessed using the chi-square test (p < 0.10 represents significant heterogeneity), and a forest plot was created using the RevMan ver. 5.4 software (p < 0.05 represents statistically significant).
Retrospective analysis
To compare the results from meta-analysis to outcomes under our own clinical settings, we have conducted a retrospective chart review of 121 patients presenting with CRAO at Univserity of Texas Health, San Antonio, TX, USA from year 2011 to 2021. Of these 121 patients, 48 have met our inclusion criteria, where 15 underwent HBOT while the other 33 patients did not receive any form of oxygen therapy. Final outcomes included change in visual acuity (VA) from presentation to the final follow-up visit and incidence of neovascular glaucoma (NVG) between the two groups. Statistical significance for the VA and NVG is analyzed using Student t-test and chi-square test, respectively. Patients with unknown time of symptom onset, patent cilioretinal artery on exam, alternative diagnoses, or those that were lost to follow-up were excluded from our retrospective study.
The protocol for HBOT is based on the US Navy diving manual [8], with hyperbaric therapy being discontinued if no improvement in VA was noted during initial treatment. If the patient noted a recovery in vision, however, additional daily hyperbaric treatments using the same protocol were administered until no further improvement was obtained.
Results
Meta-analysis outcome
As illustrated in Fig. 1 flow chart, among 376 articles screened for eligibility, three articles met the final inclusion criteria for the qualitative assessment role of HBOT in CRAO patients. The relevant information from each article is summarized in Table 1 [9-11]. The same table also includes information from retrospective analysis of results at our own university hospital (“Current study”). Comparison of results for the selected articles demonstrate that HBOT (n = 207) does not provide a significant improvement in final VA (p = 0.83) over the control (n = 89) group, as demonstrated in Fig. 2A [9-11]. Likewise, comparison of changes in the VA from initial to final presentation yields similar results, with no statistical significance (p = 0.52) between the HBOT and control groups (Fig. 2B) [9-11].
It is worth noting that the heterogeneity test for the selected studies (Fig. 2) yielded a p-value of <0.1, indicating inconsistency in the reported outcomes [9-11]. This discrepancy is most likely attributed to large differences in the baseline visual acuities in different studies, which, despite not significantly different at baseline within each study, might attribute to a source of meta-analysis conclusion bias due to large variations across studies. At the same time, owing to the lack of randomization, allocation bias might also exist within each selected study.
Retrospective analysis
Pertinent demographic information, risk factors, as well as the type of supplementary treatments that were received for each group are listed in Table 2. In the HBOT group, mean elapsed time between symptom onset and diagnosis was 9.66 ± 4.44 hours, while the mean elapsed time between symptom onset and HBOT initiation was 18.27 ± 10.4 hours. In the control group, mean elapsed time between symptom onset and diagnosis was 41.47 ± 55.59 hours. Hyperbaric treatment was stopped for three patients due to anxiety, asymptomatic bradycardia, and one patient that developed a tonic-clonic seizure. It is worth noting that the latter patient did not have an underlying seizure disorder, and further workup showed no underlying etiology for the seizure.
Analysis of our results demonstrates that there is no significant difference for initial, final, or change in VA of either group (Table 1). Likewise, incidence of NVG did not differ significantly between the treatment/HBOT (20.0%) and no-HBOT/control groups (15.2%) (p = 0.676).
Discussion
Owing to large oxygen demand, the retina is highly susceptible to ischemia, with experimental animal studies in rhesus monkeys demonstrating an irreversible damage after 105 minutes versus good recovery with up to 97-98 minutes of ischemia [12]. To counter this visually debilitating effect of CRAO, many different treatment modalities are suggested, including HBOT. The rationale for application of HBOT is the dual vascular supply of retina, with the presumption that high oxygen circulation in the choroid might provide enough oxygen diffusion to the inner retinal layers to maintain viability [13]. Nevertheless, HBOT remains an area of controversy among many ophthalmologists and this controversy is once again surfaced in our study, where visual benefit was neither observed under our clinical settings nor in the meta-analysis.
Referring to the studies in rhesus monkeys [12], given the dramatic change of visual fate over a matter of few minutes time elapse, it appears that the source of bias and controversy among reported studies might stem from the timing of treatment. For instance, in comparison to our retrospective analysis with average time elapse of 18 hours from symptom onset to oxygen therapy, other studies that show improved VA from HBOT initiated treatment within 6 to 12 hours of visual loss [9,14,15]. Therefore, it is still possible that there might be beneficial effects from very early administration of HBOT. Indeed, of the three studies selected in our meta-analysis, the visual benefits became more evident with earlier treatments, where Rozenberg et al. [11] and Beiran et al. [9] report significant improvement in the final VA with time elapse of 9 and <8 hours, respectively. A similar conclusion is also drawn in a randomized controlled trial for CRAO patients undergoing intravenous tissue-type plasminogen activator, where despite overall negative results, subgroup analysis of data demonstrates beneficial visual outcome in patients who received intravenous tissue-type plasminogen activator within 6 hours of symptoms onset [5].
It is worth mentioning that while our meta-analysis and retrospective data did not show a beneficial effect from HBOT in the setting of CRAO, per prior studies, visual benefits might exist for a select number of patients that receive treatment in the very early course of disease [16]. This is not surprising since primate studies indicate that complete or almost total optic nerve atrophy and nerve fiber damage occurs after 240 minutes of central retinal arterial occlusion [17]. Nevertheless, given the potential time elapse until diagnosis as well as subsequent delay in the setup of HBOT, it is only feasible for a small portion of patients to receive treatment within early hours of symptoms onset. In fact, a recent study by Chan et al. [18] demonstrates that presentation of CRAO patients to emergency department is often delayed, resulting in limited application of acute treatments such as intravenous thrombolysis despite having a protocol in place [18]. Of note, among the patients presented to our tertiary care center, only three have received HBOT within 8 hours of symptoms’ onset. In these patients, two have maintained stable VA of light perception and hand motion at long-term follow-up while the third patient VA decreased from hand motion to light perception.
In summary, while some individual studies conclude that early treatment of CRAO patients with HBOT improves the final VA, our meta-analysis as well as retrospective study fails to replicate a similar conclusion. Large, randomized studies are required to better understand the role of HBOT in treatment of CRAO but at the same time, strong considerations must also be made towards HBOT potential adverse effects including barotrauma, ear pain, tympanic membrane rupture, and generalized seizures due to the oxygen toxicity of the central nervous system [19].
PDF Links
PubReader
ePub Link
XML Download
Full text via DOI
Download Citation
Print
